[ad_1]
Low-dose aspirin therapy could be a new pathway for Alzheimer's disease, protecting patients' memory, according to a new study by American scientists.
According to the authors, one of the main mechanisms responsible for the progression of the disease is a loss of ability of the body to eliminate the formed plaques in the brain – especially in the hippocampus – by the toxic amyloid beta protein. Based on the badessment of a large number of studies demonstrating the link between aspirin and the reduced risk of Alzheimer's disease prevalence, scientists have shown that the drug Reduced beta-amyloid plaques in mice by stimulating the action of lysosomes – a component of animal cells that help clear cell debris.
The research, conducted by scientists from the Rush University of Chicago, was published Monday in the journal The Journal of Neuroscience. "Our study has identified a possible new role for one of the most widely used drugs in the world," said lead author Kalipada Pahan.
Up to now, the FDA – Food and Drug Administration approved for the treatment of Alzheimer's disease – which affects memory and is considered the most common type of dementia in the world – and available medications only provide limited relief of symptoms.
In the new study, researchers have low doses of aspirin, orally, to mice that have been genetically engineered to develop Alzheimer's disease. The team then badessed the amount of amyloid beta protein plaques in the areas of the brain most affected by the disease. "Aspirin stimulates lysosomes and reduces plaque buildup in animal brains."
[ad_2]
Source link
